PDL BioPharma, Inc.
PDLIV
NASDAQ
Recommendation
Prev Close
--
Volume
--
Avg Vol (90D)
--
Market Cap
--
Dividend & Yield
--
52-Week Range
-- - --
P/E (TTM)
--
EPS (TTM)
| 08/31/2020 | 06/30/2020 | 03/31/2020 | 12/31/2019 | 09/30/2019 | |
|---|---|---|---|---|---|
| Revenue | -- | -30.13% | -10.47% | -67.10% | -67.82% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -30.13% | -10.47% | -67.10% | -67.82% |
| Cost of Revenue | -- | -46.46% | -24.74% | -- | -60.05% |
| Gross Profit | -- | 1.70% | 8.25% | -- | -74.94% |
| SG&A Expenses | -- | 3.79% | 42.80% | -- | -30.41% |
| Depreciation & Amortization | -- | -2.62% | -5.03% | -- | -79.64% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -7.90% | 28.31% | -17.63% | -31.93% |
| Operating Income | -- | -10.01% | -59.90% | -408.33% | -120.05% |
| Income Before Tax | -- | -32.24% | -397.20% | -- | -142.16% |
| Income Tax Expenses | -- | 58.17% | -1,606.72% | -- | -131.68% |
| Earnings from Continuing Operations | -- | -61.29% | -275.85% | -- | -146.22% |
| Earnings from Discontinued Operations | -- | -1,167.93% | -101.62% | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | 275.79% | 357.14% | -- | -- |
| Net Income | -- | -1,030.82% | -574.90% | -437.17% | -169.59% |
| EBIT | -- | -10.01% | -59.90% | -408.33% | -120.05% |
| EBITDA | -- | -15.31% | -74.31% | -268.20% | -266.39% |
| EPS Basic | -173.89% | -1,052.67% | -597.30% | -502.52% | -188.18% |
| Normalized Basic EPS | -- | 3.80% | -44.17% | -- | -180.07% |
| EPS Diluted | -174.90% | -971.04% | -657.45% | -521.91% | -188.18% |
| Normalized Diluted EPS | -- | 3.80% | -44.17% | -- | -183.09% |
| Average Basic Shares Outstanding | -- | -2.01% | -4.58% | -18.56% | -21.08% |
| Average Diluted Shares Outstanding | 2.59% | -2.01% | -4.58% | -18.56% | -21.66% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | 0.82% | -- |